The results confirmed our hypothesis that inhibition of PI3K, Akt, or mTOR using different pharmaceutical inhibitors decreased PD‐L1 expression in a time‐dependent manner, with rapamycin (mTOR inhibitor) rapidly and persistently reducing PD‐L1 expression, indicating that the pathway plays an important role in tumor progression, not only by influencing tumor cell characteristics but also by altering the immune system in the tumor microenvironment. This evidence concerns the gene AKT1 and neoplasm.